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Objectives We sought to validate 4 angiographic measures as potential surrogates for clinical restenosis (target lesion re-
vascularization [TLR]) after stent implantation.
Background Given the low revascularization rates with drug-eluting stents (DES), an angiographic surrogate of TLR is desir-
able to reduce the sample size required to demonstrate efficacy in future trials of antirestenosis devices.
Methods We evaluated 4 potential angiographic measures (late loss [LL] and percent diameter stenosis [%DS], both in-
stent and in-segment) as a surrogate for TLR at 1 year. From 11 multicenter, prospective randomized stent tri-
als, 9 comparing DES with bare-metal stents (BMS) and 2 comparing different DES, individual data on 5,381
patients with a single treated lesion and follow-up angiography at 6 to 9 months were analyzed.
Results By 4 well-defined criteria of surrogacy, LL and %DS strongly predicted the risk of TLR, with in-segment %DS being the
most highly predictive (0.95). Differences in TLR risk were fully explained statistically by their differences in LL or
%DS, although LL as a surrogate was dependent on vessel size whereas %DS was not. However, because of the curvi-
linearity of the logistic model, trials comparing 2 effective DES can have significant differences in mean LL and %DS
but small expected differences in TLR risk, especially at the lower ranges of LL and %DS.
Conclusions From in-stent and in-segment LL and %DS measures, logistic models can reliably estimate TLR rates for DES
and BMS. These angiographic measures are thus suitable surrogate markers for clinical stent efficacy and can
be used as primary end points in future DES trials to significantly reduce sample size. (J Am Coll Cardiol 2008;
51:23–32) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.084s
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srug-eluting stents (DES) reduce angiographic restenosis
n patients undergoing percutaneous coronary intervention
PCI). The most commonly measured clinical indicator of
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oston Scientific). The database is also maintained at the CRF, and the CRF academic
tatisticians performed all the analyses in the manuscript. Drs. Pocock and Stone accept
esponsibility for the integrity of the data and the accuracy of the data analysis.r
Manuscript received April 11, 2007; revised manuscript received July 27, 2007,
ccepted July 30, 2007.tent efficacy is target lesion revascularization (TLR), which
s defined as recurrent ischemia due to angiographic reste-
osis within the stent or its margins necessitating repeat
evascularization with either PCI or coronary artery bypass
raft surgery. Of note, TLR rates are typically 30% to 60%
ower than the corresponding binary restenosis rates, sug-
esting discordance between the ischemic thresholds of
ngiographic and clinical measures of restenosis (1,2).
See page 33
iven the low rates of TLR after bare-metal stent (BMS)
mplantation in the relatively noncomplex lesions typically
tudied in stent trials, more than 2,000 enrolled patients are
equired in randomized trials to demonstrate a clinically
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Angiographic Surrogate End Points January 1/8, 2008:23–32relevant 30% reduction in TLR
with DES. Moreover, given the
low frequency clinical event rates
with DES, very large potential
differences between stents (the
“delta”) often are allowed in non-
inferiority trials to make compar-
ative DES studies practical, de-
grading confidence that the
clinical performance of 2 devices
are indeed similar.
To reduce the sample size re-
quired in superiority and nonin-
feriority trials, continuous angio-
graphic indexes of long-term
stent patency such as late lumen
loss (LL) and follow-up percent
iameter stenosis (%DS) have been proposed as surrogates
f TLR for use in randomized studies (3–5). However,
revious DES studies have suggested that the distribution of
ndividual LL measures is asymmetric with a rightward
kew and that the relation between LL and TLR is
onlinear (6,7). Whether angiographic measures are thus
alid surrogates for TLR and, if so, what cutoff values
orrespond with clinical efficacy has not been established.
hese issues have important clinical and regulatory
mplications.
To address these issues, we systematically analyzed
ooled patient-level data from 11 randomized, controlled
ES trials. Specifically, we sought to determine the appro-
riateness of using the continuous angiographic end points
f LL and follow-up %DS as surrogates of TLR after stent
mplantation; to characterize the relationship between clin-
cal and angiographic measures of stent efficacy; and to
ssess the relative value in this regard of in-stent versus
n-segment measures.
haracteristics of Studies Included in Pooled Analysis
Table 1 Characteristics of Studies Included in Pooled Analysis
Trial Name Arm 1 Arm 2
Study
Design
No. of
Patients†
TAXUS-IV Taxus (SR) Express* R, DB, MC 558
TAXUS-V Taxus (SR) Express* R, DB, MC 989
TAXUS-VI Taxus (MR) Express* R, DB, MC 417
SIRIUS Cypher BX Velocity* R, DB, MC 699
E-SIRIUS Cypher BX Velocity* R, DB, MC 319
C-SIRIUS Cypher BX Velocity* R, DB, MC 88
RAVEL Cypher BX Velocity* R, DB, MC 218
DELIVER Achieve ML Penta* R, SB, MC 442
REALITY Cypher Taxus, (SR) R, UB, MC 756
ENDEAVOR II Endeavor Driver* R, DB, MC 521
ENDEAVOR III Endeavor Cypher R, SB, MC 374
Bare-metal stent. All other stents are drug-eluting stents. †Only patients with a single lesion trea
AP Asia Pacific; Aus Australia; DB double-blind; DM diabetesmellitus; ENDEAVOR Ran
isease; LA  Latin America; MC  multicenter; MR  moderate release; R  randomized; R
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
%DS  percent diameter
stenosis
LL  late loss
MLD  minimal lumen
diameter
PCI  percutaneous
coronary intervention
RVD  reference vessel
diameter
TLR  target lesion
revascularizationevascularization; REALITY  Prospective Randomized Multi-Center Head-to-Head Comparison of the Siro
irolimus-Eluting Stent in Coronary Lesions; SR  slow release; TAXUS  Paclitaxel-Eluting Stents in theethods
tudy population and protocols. Eleven randomized stent
rials enrolling 8,726 patients were included in the analysis
etails of the study protocols have been reported previously
8–18). Protocol-specified angiographic follow-up was per-
ormed in a cohort of patients of varying size from each of
hese studies to further characterize vascular responses. In
otal, routine angiographic follow-up between 6 and 9
onths and clinical follow-up at 1 year was performed in
,381 patients with a single treated lesion, who comprise the
tudy population (Table 1). All patients at baseline had
ymptoms or objective signs of myocardial ischemia due to
oronary artery disease and at least one de novo stenosis in
native coronary artery treated with 1 or more study stents.
ine of the 11 randomized trials compared DES versus
therwise-identical BMS (8–16), and the remaining 2 trials
ompared 1 DES to another DES (Cypher vs. Taxus in
EALITY; Prospective Randomized Multi-Center Head-
o-Head Comparison of the Sirolimus-Eluting Stent
Cypher] and the Paclitaxel-Eluting Stent [Taxus] and En-
eavor vs. Cypher in ENDEAVOR III; Randomized Com-
arison of Zotarolimus-Eluting and Sirolimus-Eluting Stents
n Patients With Coronary Artery Disease) (17,18). In total,
he pooled analysis comprised 6 arms treated with
irolimus-eluting stents (Cypher, Cordis Corp., Miami,
lorida) (8–10,13,17,18), 5 arms using paclitaxel-eluting
tents (4 with the polymer-based Taxus stent [Boston
cientific, Natick, Massachusetts]) (11,14,15,17), and 1
ith a nonpolymeric paclitaxel-eluting stent (Achieve,
uidant, Indianapolis, Indiana) (12); 2 arms using
otarolimus-eluting stents (Endeavor, Medtronic, Minne-
polis, Minnesota) (16,18), and 9 arms using bare metal
tents (BX Velocity, Cordis Corp.; Express, Boston Scien-
ific; Multilink Penta, Guidant, Indianapolis, Indiana;
river, Medtronic) (8–16).
ecruiting Centers
Diabetes
Mellitus, %
Reference Vessel
Diameter, mm
Lesion
Length, mm
24.4 2.78 0.48 13.8 6.6
31.3 2.69 0.57 17.2 9.2
e 18.9 2.80 0.47 20.6 7.5
26.6 2.81 0.46 14.6 5.9
e 23.3 2.55 0.36 15.2 6.2
a 26.1 2.64 0.33 13.2 5.7
e 18.9 2.65 0.45 9.7 3.3
N/A 2.96 0.51 11.5 4.6
e LA Asia 24.9 2.42 0.47 18.4 9.4
e AP Aus Canada 20.2 2.76 0.47 13.8 5.3
28.6 2.78 0.46 15.1 6.7
follow-up angiography are included in this analysis.
d Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in PatientsWith Coronary Artery
A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for CoronaryR
U.S.
U.S.
Europ
U.S.
Europ
Canad
Europ
U.S.
Europ
Europ
U.S.
ted and
domize
AVEL limus-Eluting Stent (Cypher) and the Paclitaxel-Eluting Stent (Taxus); SB  single-blind; SIRIUS 
Treatment of Longer Lesions. Focus on Patients With Diabetes; UB  unblended.
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January 1/8, 2008:23–32 Angiographic Surrogate End PointsA wide range of de novo lesions in native coronary
rteries were evaluated in these trials. Earlier pivotal studies
nrolled patients with relatively simple lesions (RAVEL [A
andomized Comparison of a Sirolimus-Eluting Stent
ith a Standard Stent for Coronary Revascularization],
IRIUS [Sirolimus-Eluting Stent in Coronary Lesions],
AXUS-IV [Paclitaxel-Eluting Stents in the Treatment
f Longer Lesions. Focus on Patients With Diabetes],
ELIVER, ENDEAVOR II and III) (8,9,11,12,16,18).
ater studies enrolled patients with more complex lesions
otentially having greater risk of restenosis, including
-SIRIUS, C-SIRIUS, TAXUS-V, and REALITY, which
argeted lesions in small vessel (3.0 mm in diameter)
10,13,14,17), and TAXUS-V, TAXUS-VI, and REALITY,
hich enrolled patients with long lesions (30 mm in
ength) (14,15,17). Inclusion of bifurcations and ostial
esions was also allowed in the REALITY trial (17). All
ther studies excluded complex stenoses such as ostial,
ifurcation, excessive calcification, total occlusions, and
hrombus-containing lesions. In TAXUS-V, TAXUS-VI,
ll the SIRIUS trials, and REALITY trial, the use of
ultiple stents was allowed (9,10,13–15,17). In most studies,
onventional stent implantation with predilation was man-
ated (8,9,11,12,14–16,18). Direct stenting was allowed only
n E-SIRIUS, C-SIRIUS, and REALITY (10,13,17). Only
he REALITY trial allowed the enrolment of patients with
ultiple lesions (17). From the REALITY database, only
atients undergoing stent implantation in a single lesion
ere included in the present analysis.
Target lesion revascularization was defined as the need
or repeat revascularization at the site of stent implanta-
ion, including the 5 mm proximal and distal peristent
ones, with either associated ischemia or a severe
ollow-up %DS (70% by quantitative angiography). Inde-
endent clinical event committees for each trial adjudicated
ll TLR events.
ngiographic analysis methodology. All angiograms were
nalyzed by independent core laboratories: the Brigham and
omen’s Hospital, Boston, Massachusetts (9 –11,13–
6,18), Cardiovascular Research Foundation, New York,
ew York (12), and Cardialysis, Rotterdam, the Nether-
ands (8,17). Similar methodology was used in all 3 labora-
ories. Quantitative coronary angiography was performed
ith the CMS Medis system (Leiden, the Netherlands) in
ll studies but 2, in which the CASS system (PIE Medical,
aastricht, the Netherlands) was used (8,17). Measure-
ents of minimal lumen diameter (MLD) and reference
essel diameter (RVD) were performed at baseline, after
nal intervention and at follow-up, and used to calculate the
DS (1MLD/RVD) 100. In 9 trials, the RVD was
btained from averaging 5-mm segments proximal and
istal to the target lesion location, whereas the interpo-
ated RVD at the lesion site was used to calculate %DS in
trials (8,17). We calculated LL as the change in MLDrom the final post-PCI angiogram to follow-up, and it was calculated both in-stent and in the entire analysis
egment, also including the 5-mm proximal and distal
tent margins (also called in-segment).
tatistical methods. All statistical analyses were conducted
sing SAS version 9.1 (SAS Institute, Cary, North Caro-
ina). The statistical criteria for evaluating whether LL and
ollow-up %DS are useful surrogate end points for TLR
ntailed 4 main steps, as follows.
ETERMINATION OF WHETHER THE POTENTIAL SURRO-
ATE EXHIBITS STRONG CONSISTENT EVIDENCE OF
REATMENT DIFFERENCES WITHIN EACH TRIAL. For this
urpose, the z-score was used, defined as the observed
reatment difference divided by its standard error. For LL
nd %DS, this was the t statistic obtained from a 2-sample
test modified to permit unequal variances in the 2
reatment groups. For comparative purposes, the z-score
lso was obtained for the treatment difference in percentage
ith TLR. For such a difference in percentages, z is the
quare-root of the chi-square statistic. The larger the value
f z, the stronger the evidence of a treatment difference
e.g., z scores of 1.96, 3.29, and 6.11 are associated with p
alues of 0.05, 0.001, and 0.000000001, respectively).
XAMINATION OF THE STRENGTH OF THE RELATIONSHIP
ETWEEN THE POTENTIAL SURROGATE (LL OR %DS) AND
HE CLINICAL OUTCOME (TLR). For the patients in each
linical trial, the c-statistic was used to measure the strength
f association between each quantitative outcome (e.g.,
n-stent LL) and the binary outcome TLR. The c-statistic
s defined as the area under the receiver operator character-
stic curve but can be more clearly understood as follows: for
ny 2 randomly selected patients, one with and one without
LR, c is the probability that the former has the greater
alue of the quantitative surrogate. A value of c  1 means
erfect discrimination, so an effective surrogate has a value
f c close to 1.
The relationship of TLR to each of the 4 potential
urrogates LL and %DS, both in-stent and in-segment is
odeled using logistic regression applied to all 5,381
atients in the 11 trials. For a given LL the log odds of TLR
epends on the RVD, and this necessitates a bivariate
ogistic regression in which the log odds of TLR are linearly
elated to LL and to RVD grouped in 3 intervals,2.5 mm,
.5 to 3 mm, and 3 mm. These logistic models (1 for each
f the 4 potential surrogates) are then used to predict each
ndividual patient’s probability of TLR. For each treatment
roup in each trial, the predicted number with TLR equals
he sum of these individual probabilities. Actual and pre-
icted percentages of patients with TLR for all 22 treatment
roups in the 11 trials are then compared to examine the
xtent to which the potential surrogate can reliably predict
he TLR rate in these trials, and hence can be relied on to
redict the true expected TLR rate in any future trials in
hich TLR might not be actually assessed.
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Angiographic Surrogate End Points January 1/8, 2008:23–32ETERMINATION OF WHETHER THE POTENTIAL SURRO-
ATE IN EACH CLINICAL TRIAL STATISTICALLY EXPLAINS
HE OBSERVED TREATMENTDIFFERENCE IN THE CLINICAL
UTCOME. The Prentice criterion of surrogacy (19) entails
tting 2 logistic regression models to all the data within a
rial comparing DES and BMS: 1) log odds TLR  1 
1 T, where T  1 if DES, 0 if BMS; and 2) log odds
LR 2 2 T  potential surrogate (e.g., in stent
L). Then, the estimated percentage of treatment effect
xplained by the surrogate  100  (1  2)/1 %. With
perfect surrogate, the true amount explained should be 100%.
he Prentice criterion of surrogacy was explored in the 5
argest trials comparing DES and BMS, as this criterion is
est explored in large trials in which treatment differences in
he clinical outcome TLR are very pronounced.
ETERMINATION OF WHETHER THE EXTENT OF THE SIZE
F THE TREATMENT EFFECT ON TLR LINKS CLOSELY TO
HE SIZE OF THE TREATMENT EFFECT ON THE POTENTIAL
URROGATE (E.G., IN-SEGMENT LL) ACROSS ALL THE TRIAL
TUDIES. The Hughes criterion (20) of surrogacy was used
o demonstrate across trials the extent to which the magni-
ude of treatment effect on TLR is closely linked to the
agnitude of mean treatment difference in the quantitative
otential surrogates LL and %DS. This is best examined
raphically by plotting on a single scatter graph the %TLR
n the vertical axis and the mean of the potential surrogate
n the horizontal axis for each treatment group in each of
he 11 trials.
esults
he included studies and characteristics of patients with a
ingle treated lesion and angiographic follow-up are shown
n Table 1. Table 2 provides the LL, follow-up %DS, and
L, Follow-Up %DS, and 1 Year TLR Rates
Table 2 LL, Follow-Up %DS, and 1 Year TLR Rates
Trial Name
LL, mm
In-Stent In-Segment
Arm 1 Arm 2 Arm 1 Arm 2
TAXUS-IV 0.39 0.50 0.92 0.58 0.23 0.44 0.61 0.57
TAXUS-V 0.49 0.61 0.90 0.62 0.33 0.54 0.60 0.59
TAXUS-VI 0.39 0.56 0.99 0.59 0.24 0.57 0.66 0.62
SIRIUS 0.17 0.45 1.00 0.70 0.24 0.47 0.81 0.67
E-SIRIUS 0.21 0.41 1.06 0.61 0.19 0.41 0.82 0.58
C-SIRIUS 0.08 0.33 1.02 0.69 0.09 0.31 0.79 0.74
RAVEL 0.01 0.33 0.80 0.53 0.05 0.30 0.47 0.47
DELIVER 0.81 0.60 0.98 0.57 0.43 0.57 0.56 0.59
REALITY 0.09 0.38 0.30 0.42 0.04 0.35 0.16 0.39
ENDEAVOR II 0.61 0.46 1.03 0.59 0.35 0.47 0.72 0.61
ENDEAVOR III 0.60 0.48 0.15 0.35 0.34 0.44 0.12 0.33
alues are expressed as % where indicated or as mean SD.
%DS  percent diameter stenosis; LL  late loss; TLR  target lesion revascularization; other a-year TLR rates for each of the 11 trials.
0reatment difference in %DS, LL, and TLR in each
rial. For each of the 11 trials, the strength of evidence for
treatment difference in LL and %DS (both in-stent
nd -segment) expressed by the z-score (the observed
ifference in means divided by its standard error) is sum-
arized in Table 3. As shown in this table, the z-scores for
L and follow-up %DS are similar (and markedly greater
han the z-scores for TLR), signifying that LL and %DS
iscriminate equally well between treatment groups and
uch more significantly so than does TLR. For both LL
nd %DS, the z-scores were greater for the in-stent com-
ared with the in-segment measure.
he relationship of LL and follow-up %DS to the
linical outcome TLR. The c-statistic expresses the
trength of association of TLR to each of the 4 potential
urrogate end points (Table 4) and was examined for each
rial separately with individual patient data in both treatment
%DS
In-Stent In-Segment TLR Rate, %
Arm 1 Arm 2 Arm 1 Arm 2 Arm 1 Arm 2
7.4 17.7 37.2 19.8 26.3 15.4 37.8 18.5 5.3 16.5
3.1 24.6 38.9 24.8 33.6 21.8 42.3 22.3 11.2 19.0
2.2 19.2 42.8 20.9 30.4 17.4 45.4 19.7 8.7 20.3
0.4 16.5 40.3 25.3 23.6 16.4 43.4 22.5 4.9 20.2
4.6 16.0 47.5 24.7 24.6 14.6 48.8 23.3 4.6 24.9
9.3 10.6 44.2 26.5 20.5 10.3 47.8 24.5 4.0% 22.0%
4.7 7.0 36.7 18.1 25.3 9.6 38.7 16.9 0.8% 13.7%
0.9 20.8 36.2 20.9 34.7 19.1 38.9 20.1 8.8% 12.1%
6.5 14.9 22.8 15.1 28.2 14.5 30.9 14.9 4.4% 5.3%
7.7 17.5 42.4 21.7 32.6 16.4 44.5 20.4 6.0% 13.2%
4.3 17.1 11.2 16.0 29.9 15.3 23.8 14.0 6.9% 3.6%
ations as in Table 1.
-Scores* for Treatment Difference in LL and Follow-p %DS), Each for In-Stent and In-Segment, and TLRor 11 Rand miz d Trials of D ug-Eluting S ents
Table 3
Z-Scores* for Treatment Difference in LL and Follow-
Up %DS), Each for In-Stent and In-Segment, and TLR
for 11 Randomized Trials of Drug-Eluting Stents
In-Stent In-Segment
Trial LL %DS LL %DS TLR
TAXUS-IV 11.6 12.5 8.9 9.4 4.7
TAXUS-V 10.5 10.0 7.3 6.2 4.0
TAXUS-VI 10.6 10.5 7.2 8.2 3.6
SIRIUS 18.7 18.5 13.1 13.3 7.1
E-SIRIUS 14.5 14.0 11.1 11.0 6.1
C-SIRIUS 8.2 8.1 5.8 6.8 3.1
RAVEL 13.7 11.9 9.8 7.2 3.8
DELIVER 3.0 2.7 2.3 2.3 1.3
REALITY 7.4 3.3 4.5 2.5 1.1
ENDEAVOR II 9.2 8.5 7.7 7.3 4.0
ENDEAVOR III 8.3 6.5 4.4 3.4 1.1
z difference in treatment means (or percentages) divided by its standard error and summarizes
he strength of evidence for a treatment difference. z  1.96, 3.29, and 6.11 correspond to p 1
2
2
1
1
1
3
2
2
2.05, 0.001, and 0.000000001, respectively.
Abbreviations as in Tables 1 and 2.
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January 1/8, 2008:23–32 Angiographic Surrogate End Pointsroups combined. The highest c-statistic in most trials was for
he association of the in-segment %DS to TLR, with average
 0.95 across all 11 trials. The c-statistics relating TLR to
he other 3 measures (in-stent LL, in-stent %DS, and in-
egment LL) were slightly smaller, but similar to one another,
ith average c 	 0.90 across all 11 trials.
Figure 1, which combines data from all 11 trials, shows
he observed proportions with TLR for 12 intervals of LL
nd 10 intervals of follow-up %DS. For the latter, it is
vident that for any given LL the risk of TLR depends on
he RVD, whereas the relationship between follow-up %DS
nd TLR does not depend on vessel size. A sharp mono-
onic increase in the risk of TLR was present once follow-up
DS reaches 50% up to a TLR rate of 90% for patients with
DS between 70% and 90%. For the small number of
atients with %DS 90%, the observed TLR rate decreased
o 63%.
Logistic regression was used to model the relation be-
ween the 4 angiographic surrogates and TLR, adjusting for
essel size (RVD). The consequent smooth logistic curves
re shown in Figure 1. The actual regression equations
elating in-stent LL and in-segment %DS to TLR are given
n the Online Appendix.
Table 5 shows the predicted number of patients with
LR (based on the aforementioned logistic model of
n-stent LL and in-segment %DS) for each treatment group
n the 11 trials compared with the actual observed numbers.
lose agreement between predicted and actual numbers was
resent in all 44 instances, indicating that the models have
xcellent goodness of fit. This is further illustrated in the
pper graph of Figure 2, which plots the actual TLR versus
n-stent LL predicted TLR rates for all 22 treatment groups
13 DES and 9 BMS). All points are within one standard
rror of the 45° diagonal line of equality. Similar results were
-Statistics Summarizing the Strength ofssoc a on of TLR With Each of the 4 Potentialurrog e End Points With Data for All atientsBoth Groups Co bined) in Each T ial
Table 4
c-Statistics Summarizing the Strength of
Association of TLR With Each of the 4 Potential
Surrogate End Points With Data for All Patients
(Both Groups Combined) in Each Trial
In-Stent In-Segment
Trial LL %DS LL %DS
TAXUS-IV 0.90 0.94 0.92 0.97
TAXUS-V 0.88 0.90 0.91 0.95
TAXUS-VI 0.86 0.87 0.89 0.95
SIRIUS 0.88 0.90 0.92 0.95
E-SIRIUS 0.94 0.95 0.92 0.95
C-SIRIUS 0.86 0.86 0.93 0.94
RAVEL 0.98 0.93 0.91 0.95
DELIVER 0.85 0.86 0.86 0.91
REALITY 0.90 0.93 0.93 0.98
ENDEAVOR II 0.88 0.91 0.88 0.95
ENDEAVOR III 0.77 0.80 0.93 0.95
Averaged 0.88 0.90 0.91 0.95
bbreviations as in Tables 1 and 2.btained when the predicted percent with TLR was based an a logistic model relating risk of TLR to in-segment
ollow-up %DS (Fig. 2, lower graph).
elationship between treatment differences in TLR and
L or %DS. Applying the Prentice criterion of surrogacy
o the 5 largest trials comparing DES and BMS, we present
n Table 6 for each trial the percentage of treatment effect
n TLR that is explained by each of the four potential
urrogate outcomes. In-segment LL and follow-up %DS
ach explain most of the treatment effect in TLR, such that
n each trial any residual treatment effects on TLR, after
ccounting for the influence of LL and %DS, fall well short
f statistical significance. In-stent LL and follow-up %DS
ere both estimated to explain all of the treatment effect in
ost of the trials. This unusual phenomenon may be
ecause in-stent measures reflect “pure efficacy” without
aking account of edge effects, and hence tend to slightly
xaggerate the overall superiority of DES compared with
MS.
elating the size of treatment effect on TLR to the size
f treatment effects on LL and %DS. Applying the
ughes criterion of surrogacy, in Figure 3 we show the
eductions in mean LL and mean follow-up %DS (both
n-stent and in-segment) that were achieved for each trial of
DES compared with a BMS were clearly related to a
orresponding reduction in risk of TLR. Of the 4 plotted
ssociations in Figure 3, the tightest link to TLR reduction
s seen for in-segment LL. In contrast, in the REALITY
rial, which compared 2 DES with relatively low LL, the
ates of TLR were similar with the 2 devices despite a highly
ignificant difference in in-stent and in-segment mean LL
nd follow-up %DS.
iscussion
efore the availability of DES, the major limitation of PCI was
estenosis, which necessitated repeat intervention in 20% to
0% of cases after BMS implantation (21). In contrast,
urrently approved DES are notable for much lower rates of
linical and angiographic restenosis in the mostly noncomplex
esion types enrolled in the pivotal randomized trials and, as a
esult, DES have been widely adopted for the majority of
atients undergoing PCI. This new standard of care has made
t difficult to realistically evaluate next-generation DES and
ovel antirestenosis therapies because the frequencies of the
ustomary measures of clinical effectiveness (such as TLR) are
o low that very large sample sizes are required for superiority
nd noninferiority testing. Although this problem may be
vercome by restricting enrolment to high-risk lesions and
atients, recruitment rates would markedly slow, and the
esults would not be applicable to a broader cross section of
atients. Thus, the need exists for alternative measures that can
eliably be used as surrogates for TLR, allowing smaller trial
izes to accelerate evaluation of potentially more efficacious and
ost-effective DES alternatives.
Ellis et al. (6) previously demonstrated a strong associ-
tion between the continuous angiographic measure of
L
w
(
r
i
w
t
u
d
c
w
s
p
t
e
%
o
b
t
t
r
28 Pocock et al. JACC Vol. 51, No. 1, 2008
Angiographic Surrogate End Points January 1/8, 2008:23–32L and individual risk of TLR. However, this analysis
as limited by modest sample size from a single study
TAXUS-IV). The present report describing the detailed
esults of a pooled patient level analysis from 11 random-
zed contemporary DES trials involving 5,381 patients
ith systematic angiographic follow-up is the most ex-
ensive investigation to date evaluating the potential
tility of angiographic surrogates of TLR. This analysis
emonstrates that by 4 different commonly accepted
riteria of surrogacy, both LL and follow-up %DS,
Figure 1 Impact of Angiographic Measures on TLR
Proportion of patients with target lesion revascularization (TLR) as a function of in-
stratified by reference vessel diameter (RVD) using individual patient data from all
intervals of follow-up %DS. Right column  corresponding smoothed logistic curvehether measured in-stent or in-segment, are valid murrogates for TLR. The risk of TLR in individual
atients is strongly related to LL and %DS. Also, the
reatment differences in TLR rates within each trial were
ntirely explained by treatment differences in LL and
DS. This strong of a linkage has rarely been observed in
ther fields; for example, blood pressure differences
etween antihypertensive regimens do not fully explain
heir differences in risk of stroke (22). Finally, the size of
he treatment differences in %TLR linked closely to the
espective size of the mean differences for these surrogate
and in-segment late loss (LL) and follow-up percent diameter stenosis (%DS),
als. Left column  observed proportions with TLR for 12 intervals of LL and 10stent
11 tri
s.arkers, especially for in-segment LL (20).
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January 1/8, 2008:23–32 Angiographic Surrogate End PointsL as a surrogate of clinical stent efficacy. The relation-
hip between individual patient LL and risk of TLR was
ound to be well represented by a logistic curve, confirming
Figure 2 Actual Versus Predicted Rates of TLR
Actual versus predicted rates of TLR for 22 treatment groups (13 with drug-
eluting stents [DES], 9 with bare-metal stents [BMS]), using logistic models for
in-stent LL (top) and follow-up %DS (bottom). Abbreviations as in Figure 1.
omparison of Actual and LL-Predicted Numbers of Patients With Treatment Groups in 9 Trials, Based on Logistic Model Corrected f
Table 5 Comparison of Actual and LL-Predicted Numbers of PaTreatment Groups in 9 Trials, Based on Logistic Mode
Drug-Eluting Stents
Trial Actual
Predicted From
In-Stent LL
TAXUS-IV 16 17.8
TAXUS-V 51 50.4
TAXUS-VI 18 13.6
SIRIUS 20 11.6
E-SIRIUS 6 6.2
C-SIRIUS 1 0.8
RAVEL 1 1.6
DELIVER 29 30.8
ENDEAVOR II 18 24.0
REALITY, Cypher arm 12 11.0
REALITY, Taxus arm 21 19.1
ENDEAVOR III, Endeavor arm 20 25.9
ENDEAVOR III, Cypher arm 4 2.7
bbreviations as in Tables 1 and 2.Mhe observation introduced by Ellis and co-workers (6).
lthough LL would thus appear to be a useful surrogate
arker for TLR in DES versus BMS trials, the nonlinearity
f this relationship makes the use of LL as a surrogate in
omparative DES versus DES studies more problematic. In
EALITY, despite the highly significant difference in both
n-stent and in-segment late loss between Cypher and
axus, the 1-year rates of TLR were similar: 4.4% versus
.3%, respectively. Conversely, the large difference in LL
etween the Cypher and Endeavor stents in the EN-
EAVOR III trial was associated with a larger relative
ifference in TLR between the two stents (3.6% with
ypher and 6.9% with Endeavor). This disparity between
EALITY and ENDEAVOR III may be explained by
he fact that the greater LL of the Endeavor stent places
t on the rising slope of the LL-TLR relation, whereas
he mean LL of Cypher and Taxus place the majority of
atients on the flatter part of the curve where similar
bsolute differences in LL translate into smaller differ-
nces in TLR.
22ssel Size
With TLR in 22
ected for Vessel Size
Bare-Metal Stents
ted From
ment %DS Actual
Predicted From
In-Stent LL
Predicted From
In-Segment %DS
15.5 48 47.4 40.1
61.6 96 96.2 100.3
17.7 45 42.8 44.3
17.0 86 79.0 75.6
6.4 44 43.9 44.6
0.7 10 11.7 13.0
2.2 16 15.0 13.2
26.5 37 38.6 32.6
21.6 49 58 56.5
20.3 — — —
23.7 — — —
18.2 — — —
3.2 — — —
he Percentage of Treatment Effect on TLRxplained by Each of 4 Potential Surrogateutcomes* in the 5 Largest Trials C mparing Drug-l ting and Bare-Metal St s: P rcent r atmentff t Expla ed
Table 6
The Percentage of Treatment Effect on TLR
Explained by Each of 4 Potential Surrogate
Outcomes* in the 5 Largest Trials Comparing Drug-
Eluting and Bare-Metal Stents: Percent Treatment
Effect Explained
In-Stent In-Segment
Trial LL %DS LL %DS
TAXUS-IV 98 138 83 83
TAXUS-V 101 94 82 47
TAXUS-VI 115 124 75 114
SIRIUS 132 142 91 103
ENDEAVOR II 100 119 82 107
100% explained means that in a logistic model for log odds of TLR the coefficient for treatment
ffect becomes 0 when the potential surrogate (e.g., LL) is added as a second predictor variable.LR inor Ve
tients
l Corr
Predic
In-Segore than 100% explained means that the coefficient for treatment effect has changed sign.
Abbreviations as in Tables 1 and 2.
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Angiographic Surrogate End Points January 1/8, 2008:23–32ollow-up %DS as a surrogate of clinical stent effi-
acy. Follow-up %DS was equally effective as LL in pre-
icting TLR. The risk of TLR was small and nearly flat at
ess than 50% DS, increased sharply between %DS of 50%
o 80%, and then reached a plateau at greater than 80% DS.
f note, the TLR rate decreased to approximately 63% for
he small number of occluded (or near-occluded) vessels,
hich likely is explained by physician decision to treat
pproximately one-third of such patients conservatively if
linically stable or with a low likelihood of sustained vessel
atency with repeat revascularization.
The present study demonstrates that %DS and LL are
oughly equally effective surrogates. However, although it
as been argued that LL best captures the physiological
echanism whereby stents reduce TLR (3–5), several ad-
antages favor the use of %DS in practice. First, and perhaps
ost importantly, the impact of LL on the likelihood of
LR varies with vessel size, whereas the %DS–TLR rela-
ionship is vessel size independent. Second, as the difference
n 2 measures of MLD obtained from 2 different angio-
rams at different points in time, LL is inherently subject to
ore measurement error than follow-up %DS. In contrast,
DS is based on evaluation at a single time point. Finally,
DS is conceptually more intuitive and easier to apply in
linical practice than LL.
n-stent versus in-segment measures as angiographic
urrogates. In-stent LL and follow-up %DS measure-
ents both assess the magnitude of absolute and relative
Figure 3 Relationship Between Angiographic Measures and Ac
Relationship of TLR to mean LL and mean follow-up %DS both in-stent and in the a
segment for each stent treatment group in 11 randomized trials. Abbreviations aseointimal hyperplasia within the stent, providing an accu- 2ate assessment of the antiproliferative effect of DES.
owever, in-stent measures reflect only the pure biologic
otency of an antirestenotic device. In-segment measure-
ents additionally account for the magnitude of lumen
enarrowing that occurs at the margins of the stent, which
ay reflect stent/balloon mismatch, drug diffusion effects,
nd so on. Because isolated stenoses at stent edges represent
n increasingly greater proportion of TLR events with DES
han BMS (9,11), in-segment measures might be a wise
hoice as a clinical event surrogate.
se of quantitative angiographic measures to reduce
linical trial sample size requirements. Both %DS and
L had significantly greater ability to discriminate between
reatments as compared with relying on the binary outcome
LR. For instance, in each of the 5 largest trials comparing
ES and BMS, the z-score for TLR was slightly more than
alf of the z-score for in-segment LL, with a mean ratio of
.54. As a result, markedly fewer patients would be required
n a clinical trial to demonstrate efficacy using any of the
uantitative angiographic measures as primary end point
ather than binary TLR. Specifically, the number of patients
equired to detect a statistically significant treatment differ-
nce is inversely proportional to the square of the expected
-score. Hence, future trials comparing stents would require
pproximately 71% fewer patients using in-segment LL
ather than TLR as the efficacy measure (1 – 0.542  100 
1%). As discussed previously, however, for comparisons of
LR
s
res 1 and 2.tual T
nalysi
in Figu DES, both with relatively low LL, the detection of
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January 1/8, 2008:23–32 Angiographic Surrogate End Pointsignificant differences in LL or follow-up %DS does not
mply that sizeable differences in TLR exist.
It should be noted that the logistic models in the present
eport describe the relationship between individual angio-
raphic measures (LL and %DS) and the clinical efficacy
ariable TLR. The logistic models cannot be used to predict
he expected TLR rate of a specific stent cohort by simply
sing the observed group mean LL or %DS, which ignores
he width and skewness of the distribution. The predictive
ogistic models in Figure 1 and the Online Appendix may be
irectly applied, however, to any individual patient’s angio-
raphic data to provide an estimated probability of TLR. To
etermine the predicted %TLR for an entire study group,
he probability of TLR for each patient is then averaged
cross the entire study cohort to determine the expected
roup TLR rate. Such an approach is a more direct use of
he observed trial data rather than relying on the mean LL
r %DS, and avoids the need for more complex power
ransformations to remove skewness (3–5).
imitations of angiographic surrogates of TLR. Follow-up
ngiography in large studies is always 100% complete,
ost commonly because asymptomatic patients refuse re-
tudy. However, angiographic follow-up rates in the pre-
pecified angiographic cohorts were 80% in most of the
tudies in the present pooled analysis. We would thus
ecommend that future trials using angiographic measure-
ents as surrogates require similarly high rates of angio-
raphic follow-up to achieve reliable conclusions. A poten-
ial second limitation is that 3,345 of the 8,726 patients
ere not enrolled in the angiographic follow-up cohort of
he randomized trials. However, because consecutive pa-
ients from each trial were enrolled in each angiographic
ubstudy, it is likely that the study cohort of the present
nalysis is representative. Third, although blinded clinical
vent committees adjudicated all cases of TLR with discre-
ion to include only events with documented ischemia, some
LR events were driven by angiographic follow-up alone in
symptomatic patients with a severe %DS (70% by core
ab assessment, which typically corresponds to a 85%
perator assessed visual stenosis), with the rationale that
hese patients would soon likely become symptomatic and
equire revascularization. The exact frequency of which this
oculostenotic reflex” contributed to reported TLR rates in
ll the studies is unknown, but was 10% in the TAXUS-
I, -IV, -V, and -VI trials (G. Stone, unpublished data,
arch 1, 2007) and is thus unlikely to have materially
mpacted the present analysis. Nonetheless, the angio-
raphic measures discussed herein may be considered sur-
ogates for either ischemia-driven TLR, or in a small
roportion of patients, a severe recurrent angiographic
tenosis (the prevention of which is also desirable). More-
ver, routine angiographic follow-up increases TLR event
ates in patients receiving both BMS and DES, though to a
imilar relative degree (1). These biases may somewhat
ccentuate the magnitude of the TLR relationship with LL
nd %DS. TLR itself is also an imperfect measure of Mecurrent ischemia since the decision whether or not to
erform revascularization can be affected by patient and
hysician preferences. In addition, LL and %DS are surro-
ates only of TLR after stent implantation and not of the
eed for future revascularization elsewhere in the coronary
ree from pre-existing or progressive atherosclerosis in
onstented segments.
Finally, an important caveat when considering the use of
ngiographic efficacy surrogates to reduce clinical sample
ize in new device trials is that the ability to detect
ifferences in relatively low frequency safety events between
antirestenosis therapies (for which there are no acceptable
ngiographic surrogate measures) will be diminished. For
xample, previous large randomized trials demonstrated that
he achievement of greater luminal dimensions with direc-
ional atherectomy compared with balloon angioplasty was
ssociated with an increase in periprocedural myocardial
nfarction (23); such a relationship might have been missed
n a smaller trial powered for angiographic end points only.
dditional strategies are thus needed to ensure new device
afety, such as large-scale, simple randomized trials without
lanned follow-up angiography, or observational patient
egistries. In this regard, emerging devices could first be
valuated in modest-sized phase 2 studies with routine
ngiographic follow-up to demonstrate antirestenotic effi-
acy as a surrogate of low clinical TLR. Once a device has
assed this first “screening” test, a larger-scale pivotal study
without follow-up angiography) could then be performed
ith primary safety end points. Conversely, if the angio-
raphic surrogate end points for clinical efficacy are not met
n the initial study, resources can then be diverted toward
he development of more beneficial devices to improve
atient outcomes.
onclusions
pplying well-defined rigorous criteria to an extensive
atabase of randomized trials, we have demonstrated that
ithin certain constraints, LL and follow-up %DS are
uitable surrogate markers for TLR in trials evaluating DES
nd BMS. This finding has important practical and regu-
atory implications for future trials investigating the efficacy
f new DES and antirestenosis devices.
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APPENDIX
or the logistic regression equations relating in-stent LL and in-segment
DS to TLR, please see the online version of this article.
